Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertension
Peio Aristu-Zabalza(Departament de Salut), Jordi Gracia‐Sancho(University Hospital of Bern), Zoe Boyer‐Díaz, Douglas Maya‐Miles(Centro de Investigación Biomédica en Red), Sergi Guixé‐Muntet(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), María Andrés‐Rozas, Anabel Fernández-Iglesias(Centro de Investigación Biomédica en Red), David Al‐Adra(University of Wisconsin–Madison)
Cited by 0
Related Papers
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
|Clinical Nutrition|2024|44